FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Lococo Ryan

 2. Date of Event Requiring Statement (MM/DD/YYYY)
10/17/2019 

 3. Issuer Name and Ticker or Trading Symbol

MELINTA THERAPEUTICS, INC. /NEW/ [MLNT]

(Last)        (First)        (Middle)

C/O MELINTA THERAPEUTICS, INC., 44 WHIPPANY ROAD

 4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                          _____ 10% Owner
___X___ Officer (give title below)        _____ Other (specify below)
Chief Operating Officer /

(Street)

MORRISTOWN, NJ 07960      

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed(MM/DD/YYYY)

 

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person


Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		2. Amount of Securities Beneficially Owned
(Instr. 4)		3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)		2. Date Exercisable and Expiration Date
(MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		4. Conversion or Exercise Price of Derivative Security5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Melinta Common Stock  (1)6/13/2028 Melinta Stock Option (right to buy) 5620.0 $41.25 D  
Melinta Common Stock  (2) (2)Melinta Restricted Stock Units 100000.0  (2)D  
Explanation of Responses:
(1) Shares will vest 25% on the first anniversary of the award, June 14, 2019, then ratably over the following 36 months.
(2) The restricted stock units will vest in equal semi-annual installments over the two year period following May 16, 2019, subject to continued service with the Issuer through the applicable vesting date.
Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Lococo Ryan
C/O MELINTA THERAPEUTICS, INC.
44 WHIPPANY ROAD
MORRISTOWN, NJ 07960

Chief Operating Officer
Signatures
/s/ Russell E Causey, by Power of Attorney10/25/2019
**Signature of Reporting PersonDate
Melinta Therapeutics (NASDAQ:MLNT)
Gráfico Histórico do Ativo
De Out 2024 até Nov 2024 Click aqui para mais gráficos Melinta Therapeutics.
Melinta Therapeutics (NASDAQ:MLNT)
Gráfico Histórico do Ativo
De Nov 2023 até Nov 2024 Click aqui para mais gráficos Melinta Therapeutics.